Established in 2003, ABON Biopharm (Hangzhou) Co., Ltd is located in one of the most prestigious economy and technology development zones in China: the Hangzhou City Economy and Technology Development Zone. Designated as a fully owned entity of foreign investors, the ABON Biopharm(Hangzhou) Co., Ltd has been recognized by the city government as the most important foreign investment project in the area of Biotechnology in the city of Hangzhou.

The manufacture facility was designed by a San Diego, California architect firm, with garden-like building areas of approximately 30,000 sq. meters or 300,000 sq. ft. divided into manufacturing areas, R&D labs, offices and multifunctional supporting facilities. There are over 900 employees currently working in this state-of-the-art in vitro diagnostic (IVD) device manufacturing facility equipped with all the necessary amenities of a modern IVD manufacturing facility.

The designing and building of ABON Biopharm manufacturing facility was with global visions to comply with every quality system requirement established with various countries and regions.  ABON Biopharm has been registered with the U. S. FDA as a medical device establishment. It also has ISO 13485:2003 and the Japanese jGMP certifications as an IVD device manufacturing establishment. Recently the facility passed the Chinese GMP inspection. It has also registered with the regulatory agencies of Canada and Australia as a qualified medical device manufacturer to supply products to these countries.   

ABON Biopharm is thriving on innovative research, fast product development, efficient manufacturing and high volume marketing and sales of the lateral flow rapid IVD products based on an impeccable business philosophy of high quality, competitive price, flexible customer OEM product design and superior customer service. The ABON lateral flow rapid IVD products lines include tests for drugs of abuse, infectious disease, fertility, tumor markers, and cardiac markers. Many of these products are FDA 510K cleared and/or bear CE Mark. They are now commanding very good market shares in the United States, Canada, European Union, Israel, Australia, New Zealand and Japan markets.

In the near future, ABON Biopharm is poised to become the best and the largest as well as the most efficient low cost and high quality lateral flow immunoassay test producer for the world.

Since April 2006, ABON Biopharm manufacturing facility, together with its sister company Innovacon Inc. located in San Diego, California, U.S.A., has been acquired by the Inverness Medical Innovations (IMI). As ABON Biopharm is transitioning into the Inverness business family, it is positioning itself to become the global manufacturing center for the IMI organization.